Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,501 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01847209 | Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions | completed | Phase 2 | 25 | Brigham and Women's HospitalOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04895579 | Lung Cancer With Copanlisib and Durvalumab(LCD) | completed | Phase 1 | 11 | Zhonglin HaoOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04068168 |
| Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)(Imfinzi PMS) |
| completed |
| — |
| 712 |
| AstraZenecaINDUSTRY |
| 1 |
| Nov 17, 2025 |
| clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05562895 | A Multicenter Study to Evaluate the Cios Spin and the Ion Endoluminal System for Pulmonary Nodule Biopsy | completed | — | 155 | Intuitive SurgicalINDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT02812667 | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 18 | Lyudmila Bazhenova, M.D.OTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03916419 | Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer | completed | Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02823990 | TG4010 and Nivolumab in Patients With Lung Cancer | completed | Phase 2 | 13 | Megan Daly, MDOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03468426 | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | completed | Phase 1 | 252 | Boehringer IngelheimINDUSTRY | 12 | Nov 10, 2025 | clinicaltrials |
| NCT02316002 | Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 51 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03176173 | Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL) | completed | N/A | 45 | Stanford UniversityOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT03396445 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | completed | Phase 1 | 182 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Nov 5, 2025 | clinicaltrials |
| NCT03909971 | A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China | completed | Phase 2 | 109 | PfizerINDUSTRY | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02831959 | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). | completed | Phase 3 | 298 | NovoCure GmbHINDUSTRY | 15 | Oct 31, 2025 | clinicaltrials |
| NCT02477826 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)(CheckMate 227) | completed | Phase 3 | 2,747 | Bristol-Myers SquibbINDUSTRY | 33 | Oct 30, 2025 | clinicaltrials |
| NCT03694002 | Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 21 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05018208 | Remote Monitoring in Cancer Care: A Platform Study | completed | — | 100 | Mayo ClinicOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05416983 | Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung Cancer | completed | — | 37 | Mayo ClinicOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT04875195 | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | completed | Phase 2 | 66 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Oct 29, 2025 | clinicaltrials |
| NCT02599454 | Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 20 | Megan Daly, MDOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT03918304 | Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS(KOREA-PLUS) | completed | — | 923 | AstraZenecaINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT03049618 | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT05082610 | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | completed | Phase 1 | 48 | Hummingbird BioscienceINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05639751 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | completed | Phase 1 | 135 | Prelude TherapeuticsINDUSTRY | 5 | Oct 16, 2025 | clinicaltrials |
| NCT01760226 | Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies(DA-EPOCH-R) | completed | Early Phase 1 | 4 | Baylor College of MedicineOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03573947 | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC(TOP1705) | completed | Phase 2 | 46 | Jeffrey ClarkeOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05640765 | BeWell360-CG Care Model: Health and Wellness Coaching to Support Caregivers of Patients Living With Advanced Lung Cancers | completed | N/A | 55 | Mayo ClinicOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05329623 | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06180460 | CALM: Managing Distress in Malignant Brain Cancer | completed | N/A | 60 | Virginia Commonwealth UniversityOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT05308966 | Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)(MESO-IMMUNE) | completed | — | 204 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04108026 | Immunotherapy in Patient With Poor General Condition(SAVIMMUNE) | completed | Phase 2 | 50 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04215978 | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 204 | BeiGeneINDUSTRY | 8 | Oct 3, 2025 | clinicaltrials |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT03833934 | Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance(SPACEWALK) | completed | — | 62 | Addario Lung Cancer Medical InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05386888 | A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | completed | Phase 2 | 65 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06199050 | The Effect of 360° Virtual Reality Movies on Fear and Anxiety(ENGAGE) | completed | N/A | 292 | Maastricht Radiation OncologyOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05775796 | Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013) | completed | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07201077 | ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest Surgery | completed | N/A | 100 | Jianxing HeOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT01172314 | Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients | completed | N/A | 41 | Texas A&M UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04885998 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | completed | Phase 1 | 23 | AmgenINDUSTRY | 6 | Sep 29, 2025 | clinicaltrials |
| NCT02111681 | Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer | completed | N/A | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT03041311 | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC | completed | Phase 2 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT03184571 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 99 | BerGenBio ASAINDUSTRY | 4 | Sep 25, 2025 | clinicaltrials |
| NCT04589247 | Improving Cancer On-treatment Symptom Management(IMPROVE) | completed | — | 104 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04681131 | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | completed | Phase 2 | 85 | BioAtla, Inc.INDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT02719847 | EBUS TBNA After PET/CT in Diagnosing Patients With Stage I-IIA Non-small Cell Lung Cancer Evaluated for Stereotactic Body Radiation Therapy | completed | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03801902 | Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07186855 | Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC | completed | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Nov 18, 2025source: clinicaltrials